Mutation of the p53 gene in human acute myelogenous leukemia - PubMed (original) (raw)
. 1991 Apr 1;77(7):1500-7.
Affiliations
- PMID: 2009369
Free article
Mutation of the p53 gene in human acute myelogenous leukemia
J M Slingerland et al. Blood. 1991.
Free article
Abstract
Heterogeneity of p53 protein expression is seen in blast cells of patients with acute myelogenous leukemia (AML). p53 protein is detected in the blasts of certain AML patients but not in others. We have identified p53 protein variants with abnormal mobility on gel electrophoresis and/or prolonged half-life (t 1/2). We have sequenced the p53 coding sequence from primary blast cells of five AML patients and from the AML cell line (OCIM2). In OCIM2, a point mutation in codon 274 was identified that changes a valine residue to aspartic acid. A wild type p53 allele was not detected in these cells. Two point mutations (codon 135, cysteine to serine; codon 246, methionine to valine) were identified in cDNA from blasts of one AML patient. Both mutations were present in blast colonies grown from single blast progenitor cells, indicating that individual leukemia cells had sustained mutation of both p53 alleles. The cDNAs sequenced from blast samples of four other patients, including one with prolonged p53 protein t 1/2 and one with no detectable p53 protein, were fully wild type. Thus, the heterogeneity of p53 expression cannot be explained in all cases by genetic change in the p53 coding sequence. The prolonged t 1/2 of p53 protein seen in some AML blasts may therefore reflect changes not inherent to p53. A model is proposed in which mutational inactivation of p53, although not required for the evolution of neoplasia, would confer a selective advantage, favoring clonal outgrowth during disease progression.
Similar articles
- Wild-type p53 is required for apoptosis induced by growth factor deprivation in factor-dependent leukaemic cells.
Zhu YM, Bradbury DA, Russell NH. Zhu YM, et al. Br J Cancer. 1994 Mar;69(3):468-72. doi: 10.1038/bjc.1994.85. Br J Cancer. 1994. PMID: 8123475 Free PMC article. - Detection of p53 mutations in hematological malignancies: comparison between immunocytochemistry and DNA analysis.
Lepelley P, Preudhomme C, Vanrumbeke M, Quesnel B, Cosson A, Fenaux P. Lepelley P, et al. Leukemia. 1994 Aug;8(8):1342-9. Leukemia. 1994. PMID: 8057671 - p53 gene mutations with chromosome 17 abnormalities in chronic myelogenous leukemia blast crisis patients persist in long-term cell lines but may be acquired in acute myeloid leukemia cells in vitro.
Sen S, Zhou H, Andersson BS, Cork A, Freireich EJ, Stass SA. Sen S, et al. Cancer Genet Cytogenet. 1995 Jul 1;82(1):35-40. doi: 10.1016/0165-4608(94)00282-g. Cancer Genet Cytogenet. 1995. PMID: 7627932 - Mutational inactivation of the p53 gene in the human erythroid leukemic K562 cell line.
Law JC, Ritke MK, Yalowich JC, Leder GH, Ferrell RE. Law JC, et al. Leuk Res. 1993 Dec;17(12):1045-50. doi: 10.1016/0145-2126(93)90161-d. Leuk Res. 1993. PMID: 8246608 - "Acute myelogenous leukemia like" translocations in CML blast crisis: two new cases of inv(16)/t(16;16) and a review of the literature.
Patel BB, Mohamed AN, Schiffer CA. Patel BB, et al. Leuk Res. 2006 Feb;30(2):225-32. doi: 10.1016/j.leukres.2005.06.008. Epub 2005 Aug 1. Leuk Res. 2006. PMID: 16076492 Review.
Cited by
- TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Rahmé R, Braun T, Manfredi JJ, Fenaux P. Rahmé R, et al. Biomedicines. 2023 Apr 11;11(4):1152. doi: 10.3390/biomedicines11041152. Biomedicines. 2023. PMID: 37189770 Free PMC article. Review. - Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy.
Lee KS, Burke TR Jr, Park JE, Bang JK, Lee E. Lee KS, et al. Trends Pharmacol Sci. 2015 Dec;36(12):858-877. doi: 10.1016/j.tips.2015.08.013. Epub 2015 Oct 17. Trends Pharmacol Sci. 2015. PMID: 26478211 Free PMC article. Review. - Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogenetics.
Nazha A, Kantarjian HM, Bhatt VR, Nogueras-Gonzalez G, Cortes JE, Kadia T, Garcia-Manero G, Abruzzo L, Daver N, Pemmaraju N, Quintas-Cardama A, Ravandi F, Keating M, Borthakur G. Nazha A, et al. Clin Lymphoma Myeloma Leuk. 2014 Apr;14(2):163-71. doi: 10.1016/j.clml.2013.07.009. Epub 2014 Jan 22. Clin Lymphoma Myeloma Leuk. 2014. PMID: 24461514 Free PMC article. - The p53 tumor suppressor protein regulates hematopoietic stem cell fate.
Asai T, Liu Y, Bae N, Nimer SD. Asai T, et al. J Cell Physiol. 2011 Sep;226(9):2215-21. doi: 10.1002/jcp.22561. J Cell Physiol. 2011. PMID: 21660944 Free PMC article. Review. - Mechanisms of relapse in acute leukaemia: involvement of p53 mutated subclones in disease progression in acute lymphoblastic leukaemia.
Zhu YM, Foroni L, McQuaker IG, Papaioannou M, Haynes A, Russell HH. Zhu YM, et al. Br J Cancer. 1999 Mar;79(7-8):1151-7. doi: 10.1038/sj.bjc.6690183. Br J Cancer. 1999. PMID: 10098750 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous